Antengene, Cos-TCE, T-Cell Engager, Cancer Immunotherapy, TCE, CD2, CD3, Immunotherapy, SITC 2026, Preclinical Research, Oncology, Solid Tumors

Shanghai and Hong Kong, October 2, 2026 Antengene Corporation Limited has announced that it will present new preclinical results...